{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T01:56:21Z","timestamp":1772070981664,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>Patients with childhood brain tumors are at risk of endocrine disorders. The prevalence of endocrine disorders varies across the world but is unknown in Malaysia. This study\u2019s objectives were to determine the prevalence of endocrine disorders among children with brain tumors in Malaysia and to identify endocrinopathy-associated risk factors. We retrospectively reviewed the clinical data of pediatric patients with brain tumors diagnosed and treated at the University Malaya Medical Center from 1 January 2001 to 31 December 2015, with a follow-up period until the age of 18 years old or at least 3 years from the initial diagnosis. A total of 106 patients were included; 71 patients (66%) were screened for endocrine disorders, and 61% of these had endocrine disorders at a median follow-up of 4 years. Hypothyroidism, short stature, and adrenocortical insufficiency were present in one-third of the patients, followed by central diabetes insipidus (21%), growth hormone deficiency (10%), delayed puberty (9%), and precocious puberty (4%). Radiation therapy and surgical intervention were risk factors for endocrine disorders, but hydrocephalus, supratentorial tumors, and malignant tumors were not. Most endocrinopathies developed within the first 2 years of brain tumor diagnosis. Therefore, standard endocrine-monitoring guidelines aiming for early diagnosis and therapy are essential.<\/jats:p>","DOI":"10.1097\/mph.0000000000002447","type":"journal-article","created":{"date-parts":[[2022,4,21]],"date-time":"2022-04-21T16:02:51Z","timestamp":1650556971000},"page":"159-166","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence and Risk Factors for Endocrine Disorders in Childhood Brain Tumors From a Single Tertiary Center in Malaysia"],"prefix":"10.1097","volume":"44","author":[{"given":"Yean Joo","family":"Ng","sequence":"first","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Yazid","family":"Jalaludin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen Chun","family":"Foo","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Pediatrics, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Qaddoumi","sequence":"additional","affiliation":[{"name":"Department of Global Pediatric Medicine and Oncology, St. Jude Children\u2019s Research Hospital, Memphis, TN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Revathi","family":"Rajagopal","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Pediatrics, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00381-008-0771-9","article-title":"The changing epidemiology of pediatric brain tumors: a review from the Hospital for Sick Children","volume":"25","author":"Kaderali","year":"2009","journal-title":"Childs Nerv Syst"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrclinonc.2011.95","article-title":"Challenging issues in pediatric oncology","volume":"8","author":"Pui","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3122\/jabfm.2010.05.100031","article-title":"Lifetime follow-up care after childhood cancer","volume":"23","author":"Haddy","year":"2010","journal-title":"J Am Board Fam Med"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ejpn.2009.12.006","article-title":"Long-term survivors of childhood central nervous system malignancies: the experience of the Childhood Cancer Survivor Study","volume":"14","author":"Armstrong","year":"2010","journal-title":"Eur J Paediatr Neurol"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1177\/0883073809341709","article-title":"Late effects of therapy for pediatric brain tumor survivors","volume":"24","author":"Turner","year":"2009","journal-title":"J Child Neurol"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000327584","article-title":"Endocrine outcome in long-term survivors of childhood brain tumors","volume":"76","author":"Shalitin","year":"2011","journal-title":"Horm Res Paediatr"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.medici.2014.10.006","article-title":"Early development of endocrine and metabolic consequences after treatment of central nervous system tumors in children","volume":"50","author":"Ramanauskiene","year":"2014","journal-title":"Medicina (Kaunas)"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1200\/JCO.2016.67.5025","article-title":"Prevalence and risk factors of early endocrine disorders in childhood brain tumor survivors: a nationwide, multicenter study","volume":"34","author":"Clement","year":"2016","journal-title":"J Clin Oncol"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"e27631","DOI":"10.1002\/pbc.27631","article-title":"Hypothalamic-pituitary function following childhood brain tumors: analysis of prospective annual endocrine screening","volume":"66","author":"Lawson","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.21873\/invivo.11735","article-title":"Prevalence of endocrine disorders in childhood brain tumor survivors in South Korea","volume":"33","author":"Heo","year":"2019","journal-title":"In Vivo"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000336333","article-title":"Diabetes insipidus\u2014diagnosis and management","volume":"77","author":"Di Iorgi","year":"2012","journal-title":"Horm Res Paediatr"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/2230-8210.107808","article-title":"Growth and endocrine disorders in thalassemia: the international network on endocrine complications in thalassemia (I-CET) position statement and guidelines","volume":"17","author":"De Sanctis","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"R13-20250804","first-page":"76","article-title":"WHO Child Growth Standards based on length\/height, weight and age","volume":"450","year":"2006","journal-title":"Acta Paediatr Suppl"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"303","DOI":"10.11622\/smedj.2018155","article-title":"Prevalence of growth and endocrine disorders in Malaysian children with transfusion-dependent thalassemia","volume":"60","author":"Tan","year":"2019","journal-title":"Singapore Med J"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1373\/clinchem.2013.204222","article-title":"Marked biological variance in endocrine and biochemical markers in childhood: establishment of pediatric reference intervals using healthy community children from the CALIPER cohort","volume":"59","author":"Bailey","year":"2013","journal-title":"Clin Chem"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4103\/2230-8210.122620","article-title":"Cortisol response to low dose versus standard dose (back-to-back) adrenocorticotrophic stimulation tests in children and young adults with thalassemia major","volume":"17","author":"Soliman","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"57","DOI":"10.6065\/apem.2018.23.2.57","article-title":"Delayed puberty versus hypogonadism: a challenge for the pediatrician","volume":"23","author":"Bozzola","year":"2018","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"e1059","DOI":"10.1542\/peds.2008-1180","article-title":"Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls","volume":"123","author":"Houk","year":"2009","journal-title":"Pediatrics"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1200\/JCO.1999.17.7.2127","article-title":"Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children\u2019s Cancer Group Study","volume":"17","author":"Packer","year":"1999","journal-title":"J Clin Oncol"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/pbc.21525","article-title":"Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the \u201cHead Start\u201d I and II protocols","volume":"50","author":"Dhall","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R21-20250804","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejca.2017.04.019","article-title":"A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (\u226416 years) low-grade glioma\u2014a final report","volume":"81","author":"Gnekow","year":"2017","journal-title":"Eur J Cancer"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/neuonc\/nox122","article-title":"Outcome of patients with intracranial non-germinomatous germ cell tumors-lessons from the SIOP-CNS-GCT-96 trial","volume":"19","author":"Calaminus","year":"2017","journal-title":"Neuro Oncol"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/neuonc\/not019","article-title":"SIOP CNS GCT 96: final report of the outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease","volume":"15","author":"Calaminus","year":"2013","journal-title":"Neuro Oncol"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.clon.2013.07.005","article-title":"Radiotherapy in craniopharyngiomas","volume":"25","author":"Iannalfi","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/neuonc\/noq191","article-title":"Temozolomide in the treatment of high-grade gliomas in children: a report from the Children\u2019s Oncology Group","volume":"13","author":"Cohen","year":"2011","journal-title":"Neuro Oncol"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s00381-012-1890-x","article-title":"Pediatric glioblastoma: clinico-radiological profile and factors affecting the outcome","volume":"28","author":"Das","year":"2012","journal-title":"Childs Nerv Syst"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1586\/14737140.7.5.663","article-title":"Treatment of newly diagnosed diffuse brain stem gliomas in children: in search of the holy grail","volume":"7","author":"Korones","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"R28-20250804","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1440-1754.2005.00533.x","article-title":"Long-term endocrine effects of cancer treatment: experience of the Royal Children\u2019s Hospital, Melbourne","volume":"41","author":"Hameed","year":"2005","journal-title":"J Paediatr Child Health"},{"key":"R29-20250804","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1210\/jc.2019-00834","article-title":"Hypothalamic-pituitary disorders in childhood cancer survivors: prevalence, risk factors and long-term health outcomes","volume":"104","author":"van Iersel","year":"2019","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002447","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:03:21Z","timestamp":1754337801000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002447","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,25]]},"assertion":[{"value":"2021-09-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}